PF-03550096

PF-03550096
Identifiers
	IUPAC name N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-2,3-dihydro-3-(3-hydroxy-3-methylbutyl)-2-oxo-1H-benzimidazole-1-carboxamide;
CAS Number	910376-39-5 ;
PubChem CID	24857887;
ChemSpider	21378519;
UNII	E8S33VNW75;
CompTox Dashboard (EPA)	DTXSID001010008 ;
Chemical and physical data
Formula	C19H28N4O4
Molar mass	376.457 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N1C(N(CCC(C)(O)C)C2=C1C=CC=C2)=O)N[C@@H](C(C)(C)C)C(N)=O;
	InChI InChI=1S/C19H28N4O4/c1-18(2,3)14(15(20)24)21-16(25)23-13-9-7-6-8-12(13)22(17(23)26)11-10-19(4,5)27/h6-9,14,27H,10-11H2,1-5H3,(H2,20,24)(H,21,25)/t14-/m1/s1; Key:GGNIFXBIJCNXCT-CQSZACIVSA-N;

PF-03550096 is a drug that acts as a potent agonist for the CB₂ cannabinoid receptor, with good selectivity over CB₁ having K_i values of 7nM at CB₂ and 1500nM at CB₁. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,^[1] but has only progressed to animal studies.^[2]

References

^ WO 2008032164, Ando K, et al, "Benzimidazolone Derivatives", published 20 March 2008, assigned to Pfizer Products Inc.
^ Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H (February 2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of Pharmacological Sciences. 106 (2): 219–24. doi:10.1254/jphs.FP0071599. PMID 18270474.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] WO 2008032164, Ando K, et al, "Benzimidazolone Derivatives", published 20 March 2008, assigned to Pfizer Products Inc.

[2] Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H (February 2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of Pharmacological Sciences. 106 (2): 219–24. doi:10.1254/jphs.FP0071599. PMID 18270474.

[1]

[2]

See also

References